PA-EXONE
22.9.2020 14:02:08 CEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today debuted a concept rendering of the InnoventPro, a preview of the world’s most advanced entry-level binder jetting system for printing metals, ceramics and composites.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005243/en/
The InnoventPro will be a major upgrade of the Innovent+, the world’s best-selling metal binder jetting system since 2016. The InnoventPro will offer two new build sizes, a 3-liter and a 5-liter, with print speeds topping 700 cc/hour. The updated system is aimed at academics, researchers, and a full spectrum of manufacturers, from machine and MIM shops to high-volume producers, who want to produce metal parts quickly, affordably and sustainably.
“Customers around the world already love the Innovent+, and based on their feedback, we’re going to give them an updated entry-level system that’s bigger, faster and smarter than ever,” said John Hartner, ExOne CEO.
Siemens Digital Industries will serve as an Industry 4.0 collaboration partner on the production version of the machine, to be unveiled in the second half of 2021. An incentive program for the InnoventPro will be offered to customers who buy an Innovent+ prior to commercial availability of the new system. Learn more at www.exone.com/InnoventPro
Raising the bar in binder jetting
Binder jetting is a groundbreaking 3D printing process that uses a digital file to quickly inkjet a binder into a bed of powder particles — metal, sand or ceramic — creating a solid part one layer at a time. When printing metals, the final part must be sintered in order to fuse the particles together into a solid object.
Binder jetting is a sustainable method of manufacturing that reduces material waste to less than 5%, saves energy by consolidating many assembled parts and processes into one, and can deliver end-use products that are 30-40% lighter — for more efficient cars, planes and military equipment.
Importantly, the new InnoventPro will feature the same recirculating printhead modules used on the X1 25Pro® and X1 160Pro™ metal 3D printers, allowing users to easily scale up from R&D to high-volume production.
The recirculating printhead also enables ExOne’s pioneering move to offer particulate binders as an option on a commercial binder jetting system. The ExOne research team has been 3D printing a variety of nanoparticles suspended in its binders for years.
All-New Class of NanoFuse Binders
First patented in 2018 , with related patents pending worldwide, ExOne’s “inkjet-printable nanoparticle suspensions” are slated for commercial deployment in the InnoventPro. This all-new class of ExOne NanoFuse binders advances the field of binder jet 3D printing in critical ways.
Because nanoparticles fill in the interstices between powder bed particles and can bond at lower temperatures, they enable stronger green parts. In turn, this enables 3D printing of larger parts and finer features, delivering sharper corners and edges. These new binders can also improve the resolution and sinterability of high-demand metals, such as copper and aluminum.
Rick Lucas, ExOne CTO and VP, New Markets, said the InnoventPro and new NanoFuse binders show how ExOne continues to lead the way in commercial development of binder jetting.
“Just as the current Innovent+ served as the proving ground for our patented Triple ACT system, which now delivers industry-leading quality in metal binder jetting, the InnoventPro will offer groundbreaking new features in a commercial system,” Lucas said. “Our patented approach to 3D printing particulate inks in a print bed is opening new doors in binder jetting.”
ExOne’s patented Triple ACT is a critical advanced compaction technology that, depending on material, delivers industry-leading final part density of 97+%, dimensional tolerances in the range of <1%-2.5%, and high consistency, with part variation of just 0.3% across the print bed.
Triple ACT has been so effective that it has also sped up ExOne’s qualification of new materials. ExOne binder jet systems now process more than 20 metal, ceramic and composite materials , with single-alloy metals making up more than half of those offerings. NanoFuse binders are expected to expand that material range and improve sintering dynamics.
A webinar about NanoFuse will be held at 9 a.m. on Wednesday, Nov. 4. Details are available at https://tinyurl.com/NanoFuseWebinar .
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005243/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
